NKTX - Nkarta Inc Stock Price, Fair Value and News

$1.77+0.03 (+1.72%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

NKTX Price Action

Last 7 days

-3.3%

Last 30 days

-14.5%

Last 90 days

-16.9%

Trailing 12 Months

-34.4%

NKTX RSI Chart

NKTX Valuation

Market Cap

125.7M

Price/Earnings (Trailing)

-1.23

Price/Sales (Trailing)

7.41

Price/Free Cashflow

-1.34

NKTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

NKTX Fundamentals

NKTX Revenue

Revenue (TTM)

18.8M

Rev. Growth (Yr)

-29.36%

Rev. Growth (Qtr)

-6.37%

NKTX Earnings

Earnings (TTM)

-102.6M

Earnings Growth (Yr)

23.39%

Earnings Growth (Qtr)

5.49%

NKTX Profitability

Return on Equity

-30.37%

Return on Assets

-24.02%

Free Cashflow Yield

-74.41%

NKTX Investor Care

Shares Dilution (1Y)

0.65%

Diluted EPS (TTM)

-1.34

NKTX Alerts

CITADEL ADVISORS LLC reported owning 4.5% of NKTX [2024-12-13]

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	18.8M	0	0	0
2024	13.9M	16.0M	17.9M	0
2023	0	9.0M	12.0M	13.5M
2022	372.0K	954.0K	2.8M	5.6M
2021	327.3K	341.5K	355.8K	370.0K
2020	306.3K	308.5K	310.8K	313.0K
2019	0	0	0	304.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Nkarta Inc

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a lymphocyte that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, that is in phase I for the treatment of various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

CEO	Mr. Paul J. Hastings
WEBSITE	nkartatx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	169

Nkarta Inc Frequently Asked Questions

What is the ticker symbol for Nkarta Inc? What does NKTX stand for in stocks?

NKTX is the stock ticker symbol of Nkarta Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Nkarta Inc (NKTX)?

As of Wed Dec 03 2025, market cap of Nkarta Inc is 125.72 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NKTX stock?

You can check NKTX's fair value in chart for subscribers.

Is Nkarta Inc a good stock to buy?

The fair value guage provides a quick view whether NKTX is over valued or under valued. Whether Nkarta Inc is cheap or expensive depends on the assumptions which impact Nkarta Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NKTX.

What is Nkarta Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, NKTX's PE ratio (Price to Earnings) is -1.23 and Price to Sales (PS) ratio is 7.41. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NKTX PE ratio will change depending on the future growth rate expectations of investors.